24.08.2022 • News

Brenntag Buys UK Surfactants Business

Brenntag has acquired Prime Surfactants in the UK for an undisclosed sum. Headquartered in Leeds, the company is a leading distributor of surfactant specialties for the personal care and household, industrial & institutional (HI&I) industries, among other segments, in the UK.

“This acquisition enhances our product and service offering to customers in the UK and underlines our ambition to further strengthen the specialties business of our focus industries,” said Henri Nejade, member of the management board of Brenntag Group and chief operating officer of  Brenntag Specialties.

Prime Surfactants is estimated to generate sales of approximately £22 million this year. Signing and closing of the transaction took place simultaneously.

Brenntag has bought other UK businesses in past years. In January 2021, it took over ICL Packed, a specialist in distributing packaged chemicals for water treatment, and in December 2017, the German multinational group acquired Kluman and Balter, and A1 Cake Mixes which specialized in bakery ingredients and confectionary mixes.

Author: Elaine Burridge, Freelance Journalist

© Shutterstock/Monkey Business Images
© Shutterstock/Monkey Business Images

Company

Logo:

Brenntag SE

Messeallee 11
45131 Essen
Germany

Company contact







Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read